# A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

> **NCT03982186** · PHASE2 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 471 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** JNJ-73763989
- **DRUG:** Placebo for JNJ-73763989
- **DRUG:** JNJ-56136379
- **DRUG:** Placebo for JNJ-56136379
- **DRUG:** Nucleos(t)ide Analog (NA)

## Key facts

- **NCT ID:** NCT03982186
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2021-03-29
- **Final completion:** 2022-04-26
- **Target enrollment:** 471 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982186, "A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03982186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*